Dalio Says U.S. in Decline as China Rises, Warns of Election Risk

image

(Bloomberg) — Bridgewater Associates founder Ray Dalio said there’s a “reasonable chance” neither major U.S. political party will accept the results of the 2024 election.

“There is a worry that one should have about the divisiveness and what it means for each other,” Dalio said Monday during a wide-ranging interview for “The David Rubenstein Show: Peer-to-Peer Conversations,” scheduled for broadcast Feb. 2 on Bloomberg Television.

Dalio, 72, has contrasted political risks in the U.S. with recent economic growth in China. He praised the Asian country’s drive for common prosperity earlier this month while urging nations including the U.S. to narrow wealth gaps. Dalio has a net worth of $15.7 billion, according to the Bloomberg Billionaires Index.

Read more: Dalio Says U.S. Needs a Dose of China’s Common Prosperity

The U.S. is in “relative decline,” while “China has been rising,” he said in the interview.

Dalio founded Bridgewater almost four decades ago and built it into the world’s largest hedge fund. Like many of its peers, the firm’s Pure Alpha II flagship fund has struggled over the past decade, although a strong performance in December helped the fund post its best annual return since 2018.

Other highlights from the interview:

  • Dalio has a “tiny percentage” of his portfolio in cryptocurrencies but said too much attention is spent on them.

  • The Federal Reserve has been “behind the curve” on monetary policy, he said. “Rising interest rates means all other assets have to adjust.”

  • With negative real interest rates, it doesn’t pay to hold cash, Dalio said, noting that the average investor should expect annual returns of about 4%.

(Updates with comment on China in the fourth paragraph)

Most Read from Bloomberg Businessweek

©2022 Bloomberg L.P.

 
Trending Ideas

Featured Stocks On The Move

Daily Rundown

Top 3 Stocks in Leading Sectors
  • 3 Software Stocks To Buy Now

    International Business Machines Corporation (IBM) International Business Machines Corporation (IBM) is a global leader in cloud computing, AI, and enterprise software. The company provides IT infrastructure, cybersecurity, and quantum computing... Read More

  • 3 Food Stocks To Buy Now

    The Campbell’s Company (CPB) The Campbell’s Company is a leading producer of packaged foods and beverages, known for its soups, sauces, and snacks. With brands like Campbell’s, Pepperidge Farm, and... Read More

  • 3 Utility Stocks To Buy Now

    IDACORP, Inc. (IDA) IDACORP, Inc. is a utility holding company that provides electricity through its subsidiary, Idaho Power. The company focuses on renewable energy initiatives, grid modernization, and sustainable power... Read More

  • 3 Biotechnology Stocks To Buy Now

    Xeris Biopharma Holdings, Inc. (XERS) Xeris Biopharma Holdings, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative injectable drug formulations. Its proprietary technology enhances drug stability and... Read More

  • 3 Consumer Service Stocks To Buy Now

    TripAdvisor, Inc. (TRIP) TripAdvisor, Inc. operates the world’s largest travel guidance platform, offering user-generated reviews, price comparisons, and booking services for hotels, attractions, and restaurants worldwide. Chart Wynn Resorts, Limited... Read More

  • 3 Software Stocks To Buy Now

    Udemy, Inc. (UDMY) Udemy, Inc. is an online learning platform offering a vast catalog of courses across various fields. The company connects learners with expert instructors, providing affordable and accessible... Read More

  • 3 Energy Stocks To Buy Now

    Ranger Energy Services, Inc. (RNGR) Ranger Energy Services, Inc. provides well services and support for oil and gas production. The company specializes in high-spec rig solutions, completion services, and workover... Read More

  • 3 Pharmaceutical Stocks To Buy Now

    ACADIA Pharmaceuticals Inc. (ACAD) ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on developing therapies for central nervous system disorders. The company’s lead product, NUPLAZID, is used to treat Parkinson’s... Read More